GOSSAMER BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 211.46K shares, a 87.77% increase year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 1.04M shares.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 438.35K shares.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.69M shares.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 270.71K shares, a 16.83% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 1.69M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 211.46K shares 10-Q · filed 2026-05-15 | 1.79M shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 1.04M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 1.69M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 438.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 652.23K shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | 101.27K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 213.88K shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | 112.62K shares 10-Q · filed 2025-05-15 | 112.62K shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 0.00 shares 10-K · filed 2026-03-17 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 0.00 shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 0.00 shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-07 | 0.00 shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 0.00 shares 10-K · filed 2026-03-17 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 1.60K shares derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 223.18K shares derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-09 | 231.18K shares derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | 1.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 270.71K shares 10-K · filed 2025-03-13 |
| 2022-09-30 | 221.57K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 313.70K shares derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | 8.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 263.38K shares derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | 39.52K shares 10-Q · filed 2022-05-10 | 359.30K shares derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | 44.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | 325.49K shares 10-K · filed 2024-03-05 |
| 2021-09-30 | 171.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 339.42K shares derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | 103.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 200.44K shares derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | 5.72K shares 10-Q · filed 2021-05-06 | 136.22K shares derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | 58.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 134.80K shares 10-K · filed 2023-03-17 |
| 2020-09-30 | 32.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 322.16K shares derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | 39.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | 402.83K shares derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | 4.31K shares 10-Q · filed 2020-05-12 | 396.40K shares derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | 245.88K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | 419.59K shares 10-K · filed 2022-03-03 |
| 2019-09-30 | 112.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2019-06-30 | 33.27K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | |
| 2019-03-31 | 27.50K shares 10-Q · filed 2019-05-14 | |
| 2018-12-31 | 0.00 shares 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |